Without a specific news headline driving the move, DexCom (DXCM) sits at a recent close of US$70.69, leaving investors weighing its continuous glucose monitoring business against recent share price ...

In the preceding three months, 12 analysts have released ratings for DexCom (NASDAQ:DXCM), presenting a wide array of ...

Intuitive Surgical, the leader in the robotic-assisted surgery (RAS) market, encountered at least two obstacles in 2025. First, tariffs took a bite out of the company's financial results. Second, ...

BTIG analysts continue to expect growth from Dexcom (Nasdaq:DXCM) after meeting with the company's senior investor relations (IR) officials.

DexCom has underperformed the Nasdaq Composite over the past year, yet analysts remain highly optimistic about the stock’s ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

One underappreciated reason why I feel DXCM could potentially gain more favorable interest is because its long-suffering ...

Dexcom will stop producing G6 CGM sensors July 1, 2026, urging patients to switch to the smaller, more accurate G7 model.

(Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2025.

March 6 (Reuters) - Medtronic's diabetes business MiniMed fetched a $5.35 billion valuation after its shares opened 4.8% ...

MiniMed (MMED) shares drop 4.8% in Nasdaq debut, opening at $19.05 after raising $560M in IPO. Medtronic (MDT) retains 90% stake in diabetes device spinoff.

Investing.com -- Medical technology (MedTech) stocks have faced meaningful pressure in recent years, and analysts at Piper Sandler suggest the sector’s turnaround may still be several quarters away, ...